Company Overview and News

2
Sinclair Tries to Appease F.C.C., but Its Tribune Bid Is Challenged - The New York Times

38m nytimes
Sinclair Broadcast Group, the largest local television operator in the United States, tried to placate federal regulators on Wednesday regarding its proposal to buy a rival TV group. But the Federal Communications Commission still voted unanimously to have a judge review aspects of the deal, a potentially ominous sign for the merger.
TRBNW NYTAB SBGI TRCO TRBAB

9
Google Remains Strong After Antitrust Fine from EU

1h zacks
In recent news, Alphabet Inc. (GOOGL - Free Report) was hit by a record-breaking $5 billion fine by EU regulators for breaking antitrust laws. According to The New York Times, this steep antitrust penalty is among one of the most aggressive regulatory moves ever made against an American technology company. The fine comes from Google abusing its Android market dominance in three different areas. The three areas outlined include Google bundling its search engine and Chrome apps into the operating system; blocking phone makers from creating devices that run forked versions of Android; and paying large manufacturers to bundle the Google search app on handsets, according to The Verge.
FB SAP SAPGF GOOGL MSFT NYTAB GOOG INTC

0
Did Goldman Sachs Just Edge Away From Its Bonus Culture? - The New York Times

1h nytimes
Get the DealBook newsletter to make sense of major business and policy headlines — and the power-brokers who shape them.
NYTAB

0
Nike Says Its $250 Running Shoes Will Make You Run Much Faster. What if That’s Actually True? - The New York Times

1h nytimes
If a running shoe made you 25 percent faster, would it be fair to wear it in a race? What about 10 percent? Or 2 percent? The Nike Zoom Vaporfly 4% — a bouncy, expensive shoe released to the public one year ago — raises these questions like no shoe in recent distance running history.
NYTAB

0
High child-care costs are driving Americans away from parenthood — Quartz

2h qz
American adults are having fewer kids—or foregoing parenthood entirely. A new survey conducted by Morning Consult for The New York Times sheds light on the dynamics behind the trend.
NYTAB

0
A Brief History of the Impact of E.U. Antitrust Fines on Tech Stocks - The New York Times

2h nytimes
Get the DealBook newsletter to make sense of major business and policy headlines — and the power-brokers who shape them. __________
NYTAB

40
5 Top Stock Trades for Thursday Morning

3h investorplace
Wednesday was a relatively mellow day for U.S. stocks, as many equities consolidated their gains from the prior session. That allowed some high-quality setups to emerge, helping us pluck out a few top stock trades.
OSTK X SQ JPM NYTAB EBAY

19
Why Is Comcast Stock Down? It May Not Be Quite What You Think.

3h investorplace
Ask ten Comcast (NASDAQ:CMCSA) shareholders if they really wanted the company to get into a bidding war with Walt Disney (NYSE:DIS) for most of Twenty-First Century Fox (NASDAQ:FOXA), and you’ll get ten different answers. By and large though, a common and unspoken response to Comcast’s probably bowing out of the race for Fox is “whew… expensive bullet dodged.”
FOX T CMCSA TWX NFLX NYTAB TWC FOXA DIS

0
Barack Obama on wealth inequality: ‘There’s only so much you can eat’

3h cnbc
Former United States President Barack Obama believes that ballooning wealth inequality is a threat to society, and that those who have the means should help those who are less fortunate.
NYTAB

0
Elon Musk Walks Back ‘Pedo Guy’ Attack on Cave Diver After Investor Pressure - The New York Times

3h nytimes
The tech billionaire Elon Musk on Wednesday walked back his baseless claim that a British diver involved in the cave rescue efforts in Thailand was a pedophile, an accusation made after the man criticized a submarine that Mr. Musk had said he built to help with the rescue.
NYTAB

7
How Big Formula influences parents from the supermarket to Trump's White House

5h abc.net.au
Infant formula is a wonder product for some working mums and those who can't or don't want to breastfeed.
ABT NYTAB ABT

3
7 Cybersecurity Funds for Growth Investors | InvestorPlace

5h investorplace
Over the past several years, cybersecurity has emerged as one of the hottest themes in the broader technology sector. Data suggest it could also be one of the most durable technology investment themes over the long-term.
STT STT.PRC STT.PRE XKFS STT.PRD STT.PRG DTEC CSCO NYTAB AIQ CIBR

0
George Soros Bet Big on Liberal Democracy. Now He Fears He Is Losing. - The New York Times

6h nytimes
His enemies paint him as all-powerful, but the billionaire philanthropist believes that his political legacy has never been in greater jeopardy.
NYTAB

0
‘When Harry Met Sally’ director on film’s 30th anniversary–and that orgasm scene

6h entertainment.inquirer.net
LOS ANGELES—It’s been almost 30 years since Meg Ryan’s unforgettable orgasm scene in “When Harry Met Sally.” So when we recently interviewed that movie’s director, Rob Reiner, we pounced on the chance to talk to him about its milestone next year.
NYTAB

5
The Price of Bitcoin Jumped Yesterday... Is There Hope for the Bulls? | InvestorPlace

8h investorplace
The price of bitcoin rose sharply on July 18, giving hope that the bear market in cryptocurrency may be ending.
GS BLK NFLX NYTAB

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...